Illumina Countersues IBS and Qiagen for Patent Infringement

Illumina Countersues IBS and Qiagen for Patent Infringement

Kevin Williams, MDInvestor Relations858-332-4989orJennifer TemplePublic Relations858-882-6822

Illumina, Inc. (NASDAQ: ILMN) today announced that the company has sought leave to file counterclaims against Intelligent Bio-Systems, Inc. (IBS) and Qiagen NV, which recently acquired IBS, in response to the patent lawsuit brought by Columbia University and IBS on March 26, 2012 in U.S. District Court in Wilmington, Delaware. In its counterclaims, Illumina has sued IBS and Qiagen for infringement of three Illumina patents, entitled “Labelled Nucleotides.” These three patents (U.S. Patent Nos. 7,057,026; 7,785,796; and 8,158,346, all expiring in December 2022), are applicable to the sequencing by synthesis technology being used in the IBS Max-Seq and MINI-20 DNA Sequencers. Illumina is seeking all available remedies, including injunctive relief. With respect to the claims brought by Columbia and IBS, Illumina has denied all of Columbia’s and IBS’s allegations of patent infringement, and has asserted that Columbia’s patents are invalid.

Illumina is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. Illumina owns or has exclusive licenses to more than 250 patents granted in the U.S., and many additional patents granted worldwide, to protect its massive investments in research and development and resulting technological breakthroughs.

“As we have said in the past, Illumina strongly prefers to compete in the marketplace. However, we are determined to use our IP to protect our market position, acquired through Illumina’s history of unmatched innovation, so that our customers can continue to benefit from resulting technological advances that are changing the economics of genetic research,” said Jay Flatley, President and CEO of Illumina.

Illumina () is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.

This release may contain forward looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.

Suggested Articles

The back-to-back pivotal successes tee Incyte up to talk to regulators about bringing the JAK inhibitor to market.

The judge also ordered Reynolds to pay $280,000 in forfeiture and around $7.5 million in restitution as punishment for his crimes. 

NeoTX Therapeutics has nabbed a healthy $45 million third funding round as it looks to continue work on its early-stage cancer combo test.